← All trials
NCT05154747
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Dec 13, 2021
- Last posted
- Dec 13, 2021
- Enrollment
- 460
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LondonLead sponsor
- Johnson and JohnsonCollaborator
- Radboud UniversityCollaborator
- University of LondonCollaborator
- ViiV HealthcareCollaborator
- University of YorkCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- PENTA FoundationCollaborator
- Medical Research Council-UVRI Uganda Research Unit on AIDSCollaborator
- Africa Health Research InstituteCollaborator
- University of LondonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.